Article
Oncology
Stefan Aebi, Per Karlsson, Irene L. Wapnir
Summary: Locally advanced breast cancer refers to breast adenocarcinoma that is inoperable without distant metastasis. A multidisciplinary approach is required for the treatment of patients with locally advanced breast cancer. Staging exams are necessary to assess the risk of distant metastasis. The incidence of locally advanced breast cancer has decreased in recent years. Treatment strategies for locally advanced breast cancer are often extrapolated from studies on patients with less or more advanced disease. Pathologic confirmation and molecular profiling are essential for determining the appropriate neoadjuvant chemotherapy. Preoperative endocrine therapy and targeted therapies are being investigated for certain clinical situations. Promising results have been observed with anti-HER2 agents in HER2 positive locally advanced breast cancer, and PD-1 and PD-L1 antibodies show potential in 'triple-negative' locally advanced breast cancer. Neoadjuvant therapy can lead to conservative surgery in many patients, but mastectomy may still be necessary for inflammatory breast cancer. Postoperative radiotherapy is usually recommended. Multidisciplinary teams play a crucial role in optimizing local control and preventing relapse. However, there is a need for specific research efforts to further improve the survival outcomes for patients with locally advanced breast cancer.
Review
Oncology
Kadhim Taqi, Jin-Si Pao, Leo Chen, Crystal Ma, Mabel Zhang, Elaine McKevitt, Amy Bazzarelli, Carol Dingee, Rebecca Warburton
Summary: Immediate breast reconstruction (IBR) following mastectomy is a safe option for patients with locally advanced breast cancer, with higher overall survival compared to mastectomy alone. However, it does not have significant impact on disease-specific survival, disease-free survival, local recurrence, adjuvant therapy use, or reoperation rates.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Line Hoeltgen, Eva Meixner, Philipp Hoegen, Elisabetta Sandrini, Fabian Weykamp, Tobias Forster, Maria Vinsensia, Kristin Lang, Laila Koenig, Nathalie Arians, Carlo Fremd, Laura L. Michel, Katharina Smetanay, Andreas Schneeweiss, Markus Wallwiener, Juergen Debus, Juliane Hoerner-Rieber
Summary: This study aimed to investigate the benefit of radiotherapy for symptom relief in women with locally advanced breast cancer or inoperable local recurrence. The results showed that radiotherapy effectively controlled local symptoms with only mild toxicity. Therefore, early consideration of radiotherapy in palliative care management can improve patients' quality of life.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2023)
Article
Medicine, General & Internal
Deborah Schrag, Qian Shi, Martin R. Weiser, Marc J. Gollub, Leonard B. Saltz, Benjamin L. Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn A. Goodman, Robert R. McWilliams, Jeffrey M. Farma, Thomas J. George, Hagen F. Kennecke, Ardaman Shergill, Michael Montemurro, Garth D. Nelson, Brian Colgrove, Vallerie Gordon, Alan P. Venook, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Amylou C. Dueck, Ethan Basch, George J. Chang, Harvey J. Mamon
Summary: Preoperative FOLFOX chemotherapy is as effective as preoperative chemoradiotherapy for locally advanced rectal cancer eligible for sphincter-sparing surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Chemistry, Medicinal
Xiangyi Kong, Jiarui Song, Peng Gao, Ran Gao, Lin Zhang, Yi Fang, Yipeng Wang, Jidong Gao, Jing Wang
Summary: Locally advanced breast cancer (LABC) continues to pose a significant clinical challenge despite advancements in diagnostic and therapeutic technologies. Preoperative neoadjuvant radiotherapy (NART) has shown potential in reducing tumor volume and improving quality of life for LABC patients, but it remains underexplored in clinical studies.
MEDICINAL RESEARCH REVIEWS
(2023)
Article
Oncology
Ishita Chen, Astrid M. Botty Van den Bruele, Erin F. Gillespie, Boris A. Mueller, Amy J. Xu, John Cuaron, Atif J. Khan, Beryl McCormick, Oren Cahlon, Simon N. Powell, Hiram Cody, Lior Z. Braunstein
Summary: This study evaluated the safety and efficacy of repeat breast conservation using a novel radiotherapy regimen as salvage therapy for recurrent breast cancer. With a median follow-up of 23.5 months, the study found excellent local control with low toxicity rates. Further research with longer follow-up in larger cohorts is needed to determine the long-term outcomes of this treatment approach.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Medicine, General & Internal
Amelia M. Taylor, David Lok Hang Chan, Martin Tio, Sujata M. Patil, Tiffany A. Traina, Mark E. Robson, Mustafa Khasraw
Summary: PARP inhibitors show potential benefits in improving survival and tumor response rates in patients with locally advanced or metastatic HER2-negative, BRCA germline mutated breast cancer. More research is needed to further explore the impact of PARP inhibitors on quality of life outcomes and their role in other relevant breast cancer populations.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Multidisciplinary Sciences
Kristi Kruger, Laxmi Silwal-Pandit, Elisabeth Wik, Oddbjorn Straume, Ingunn M. Stefansson, Elin Borgen, Oystein Garred, Bjorn Naume, Olav Engebraaten, Lars A. Akslen
Summary: High baseline microvessel density (MVD) significantly predicted response to bevacizumab treatment, while high proliferative microvessel density (pMVD), glomeruloid microvascular proliferation (GMP), and the angiogenesis signature score did not predict pathologic complete response (pCR) but were associated with aggressive tumor features.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Gabriela Bezerra Nobrega, Bruna Salani Mota, Gabriela Boufelli de Freitas, Jonathan Yugo Maesaka, Rosa Maria Salani Mota, Rodrigo Goncalves, Angela Francisca Trinconi, Marcos Desiderio Ricci, Jose Roberto Piato, Jose Maria Soares-Jr, Edmund Chada Baracat, Jose Roberto Filassi
Summary: BCS is associated with superior OS rates compared to MS in patients with LABC following NAT. Lower BMI, lower pretreatment stage, and achieving PCR were associated with improved survival outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Chandler Coleman, Connie H. Yan, Naomi Y. Ko, Nadia A. Nabulsi, Kent F. Hoskins, Brian C-H Chiu, Gregory S. Calip
Summary: This study investigated the associations between physical functioning and frailty with the risk of locally-advanced breast cancer. Results suggested that worse physical function was associated with an increased risk of locally-advanced breast cancer, while frailty was not.
Article
Biochemistry & Molecular Biology
Montserrat Justo-Garrido, Alejandro Lopez-Saavedra, Nicolas Alcaraz, Carlo C. Cortes-Gonzalez, Luis F. Onate-Ocana, Claudia Haydee Sarai Caro-Sanchez, Clementina Castro-Hernandez, Cristian Arriaga-Canon, Jose Diaz-Chavez, Luis A. Herrera
Summary: Chemoresistance to standard neoadjuvant treatment is common in locally advanced breast cancer, particularly in the luminal subtype. Identifying genes associated with chemoresistance is crucial for understanding mechanisms and finding effective treatments. This study aimed to identify genes linked to neoadjuvant chemotherapy resistance in patients with luminal breast cancer. Whole RNA sequencing of patient biopsies revealed 269 differentially expressed genes in chemoresistant patients and validated eight highly correlated genes. SLC12A1 and GRIA4, both involved in ion transport, showed the strongest association with chemoresistance. Findings suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Neslihan Cabioglu, Aysel Bayram, Selman Emiroglu, Semen Onder, Huseyin Karatay, Gizem Oner, Mustafa Tukenmez, Mahmut Muslumanoglu, Abdullah Igci, Adnan Aydiner, Pinar Saip, Ekrem Yavuz, Vahit Ozmen
Summary: This study investigates the expression of new immune checkpoint receptors CD155 and CD73 in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy. The results show that high expression of CD155 is associated with a poor chemotherapy response and prognosis. The coexpression of CD155 and CD73 results in a worse outcome than either marker alone, highlighting the need for further investigation.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Yujiao Deng, Hongtao Li, Yi Zheng, Zhen Zhai, Meng Wang, Shuai Lin, Yizhen Li, Bajin Wei, Peng Xu, Ying Wu, Xinyue Deng, Si Yang, Jun Lyu, Jingjing Hu, Huaying Dong, Zhijun Dai
Summary: Patients with locally advanced breast cancer (LABC) who underwent postoperative radiotherapy showed improved overall survival compared to those who received preoperative radiotherapy, indicating that preoperative radiotherapy did not present a better survival outcome than postoperative radiotherapy for LABC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Florian Schwarz, Habibollah Arefian, Michael Hartmann, Ingo Runnebaum
Summary: This study evaluated the cost-effectiveness factors of talazoparib for patients with a germline breast-cancer-gene (brca) mutation and locally advanced or metastasized breast cancer in the German healthcare system. The findings suggest that talazoparib is not cost-effective at current pricing.
Article
Oncology
Omar Picado, Deukwoo Kwon, Kristin Rojas, Jessica Crystal, Lora Wang, Reshma Mahtani, Frances Valdes, Neha Goel, Susan B. Kesmodel
Summary: In locally advanced breast cancer, genomic profiling is not predictive and endocrine therapy alone is associated with worse overall survival compared to combined chemotherapy and endocrine therapy.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
